Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to Δ9- tetrahydrocannabinol

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 664-673

  McKinney, Diana L ^a   Cassidy, Michael P ^a   Collier, Lauren M ^a   Martin, Billy R ^a   Wiley, Jenny L ^a   Selley, Dana E ^a   Sim Selley, Laura J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; DRONABINOL; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG INHIBITION; DRUG TOLERANCE; ENTOPEDUNCULAR NUCLEUS; GLOBUS PALLIDUS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADAPTATION, BIOLOGICAL; ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; MALE; MICE; MICE, INBRED ICR; PROTEIN BINDING; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL;

EID: 38749093701     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.130328     Document Type: Article

References (44)

1. Arriza JL, Dawson TM, Simerly RB, Martin LJ, Caron MG, Snyder SH, and Lefkowitz RJ (1992) The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain. J Neurosci 12:4045-4055.
2. Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, Snyder SH, Caron MG, and Lefkowitz RJ (1992) Beta-arrestin2, a novel member of the arrestin/ beta-arrestin gene family. J Biol Chem 267:17882-17890.
3. Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, and Martin BR (2002) SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacol Biochem Behav 74:31-40.
4. Bass CE and Martin BR (2000) Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60:113-119.
5. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, and Sim-Selley LJ (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptor-activated G-proteins in brain. J Neurochem 73:2447-2459.
7. Breivogel CS, Griffin G, Di Marzo V, and Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163.
8. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873.
9. Carlini EA (1968) Tolerance to chronic administration of cannabis sativa (marihuana) in rats. Pharmacology 1:135-142.
10. De Vry J, Jentzsch KR, Kuhl E, and Eckel G (2004) Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol 15:1-12.
11. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
12. Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, and Hollt V (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Mol Brain Res 95:129-137.
13. 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271:1383-1390.
14. Gurevich EV, Benovic JL, and Gurevich VV (2002) Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109:421-436.
15. Haney M, Ward AS, Comer SD, Foltin RW, and Fischman MW (1999) Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl) 141:385-394.
16. Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, and Fischman MW (2002) Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 164:407-415.
17. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
19. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, and Mackie K (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-3780.
20. Jones RT, Benowitz N, and Bachman J (1976) Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 282:221-239.
21. Jones RT, Benowitz NL, and Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21:143S-152S.
22. Kirk JM and de Wit H (1999) Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacol Biochem Behav 63:137-142.
23. Le Foll B and Goldberg SR (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875-883.
24. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404.
25. Lichtman AH, Cook SA, and Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593.
26. Mackie K and Stella N (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8:E298-E306.
27. McMillan DE, Dewey WL, and Harris LS (1971) Characteristics of tetrahydrocannabinol tolerance. Ann N Y Acad Sci 191:83-99.
28. Oviedo A, Glowa J, and Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 616:293-302.
29. Piomelli D, Giuffrida A, Calignano A, and Rodriguez de Fonseca F (2000) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218-224.
30. Rawls SM, Cabassa J, Geller EB, and Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4- morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)- 6H-pyrrolo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963-968.
31. Richardson D, Ortori CA, Chapman V, Kendall DA, and Barrett DA (2007) Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal Biochem 360:216-226.
32. Rubino T, Forlani G, Vigano D, Zippel R, and Parolaro D (2005) Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. J Neurochem 93:984-991.
33. Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G, and Parolaro D (2000) Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39:1331-1336.
34. Sañudo-Peña MC, Romero J, Seale GE, Fernandez-Ruiz JJ, and Walker JM (2000) Activational role of cannabinoids on movement. Eur J Pharmacol 391:269-274.
35. Schlicker E and Kathmann M (2001) Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22:565-572.
36. B-mediated inhibition of adenylyl cyclase in mouse cerebellum. Mol Pharmacol 66:1275-1284.
37. 35S]GTPγS autoradiography in rat brain. J Neurosci 16:8057-8066.
38. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91-119.
39. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, and Selley DE (2006) Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70:986-996.
40. Tappe-Theodor A, Agarwal N, Katona I, Rubino T, Martini L, Swiercz J, Mackie K, Monyer H, Parolaro D, Whistler J, et al. (2007) A molecular basis of analgesic tolerance to cannabinoids. J Neurosci 27:4165-4177.
41. van der Stelt M and Di Marzo V (2003) The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150.
42. Villares J (2007) Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 145:323-334.
43. Whitlow CT, Freedland CS, and Porrino LJ (2003) Functional consequences of the repeated administration of Delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 71:169-177.
44. Wiley JL, Smith FL, Razdan RK, and Dewey WL (2005) Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur J Pharmacol 510:59-68.